Biotech
Aug. 11, 2011
Barbara A. Kosacz
Kosacz said it's tough to finance biotechnology companies right now, even though people continue to get sick and develop medical conditions, and Baby Boomers are aging.
"You have a lot less money going into pharmaceuticals," she said.
Uncertainty around U.S. Food and Drug Administration review and approval has scared many investors - both venture capitalists and stock market investors - away from biotech and medical device com...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In